Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises un
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... Inc. announced today that it has reached agreement with ... to incorporate its glucose sensor into Luminous, automated blood ... enable clinicians to control hyperglycemia in critical care patients ... use a sensing technology based on near-infrared spectrometry. ...
... , Four Companies Required to Stop Making and ... Md., Oct. 13 The U.S. Food and Drug ... marketing unapproved codeine sulfate tablets. These drugs are opioid ... treat pain. , (Logo: ...
Cached Medicine Technology:Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 2FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets 3
(Date:12/20/2014)... AZ (PRWEB) December 20, 2014 Parker ... professional technicians with years of experience in contractor services ... dedicated contractor services for the homeowners of Arizona. Parker ... team a professional contractor technicians that make customer service ... 1974 in Phoenix Arizona and started with one service ...
(Date:12/19/2014)... Sweetdressy.com , a leading wedding dress ... selection of cheap prom dresses for ladies worldwide. The ... world and clients can buy these dresses at the ... feature cool cuts and delicate craftsmanship, and most of ... market. Discount shipping costs are available for all of ...
(Date:12/19/2014)... Silver Dollar City is picking up ... the first time ever, Silver Dollar City has a title ... 2015, listing the park’s wood coaster Outlaw Run as the ... announced this week, Silver Dollar City is named in CNN ... USA Today’s 10Best awards for “Best Public Lights Display,” and ...
(Date:12/19/2014)... An evening dress is perfect for any ... Discount-Dress.com, a distinguished dresses retailer, has unveiled its new selection ... this great shopping platform. Customers can view more ... work, Discount-Dress.com has been accepted and praised by customers for ... shopping stage for clients. In order to expand its market ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The intestinal bacteria ... and ulcerative colitis, may be inherited, researchers report. ... Medicine , could help in efforts to prevent the ... or colitis, the study authors added. "The intestinal ... young age can have a big impact on your ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2
... CUPERTINO, Calif., Feb. 29 DURECT Corporation,(Nasdaq: ... and Chief,Executive Officer, will be presenting at the ... Financial Group on Tuesday,March 4, 2008 at 2:45 ... the W,Hotel, 541 Lexington Avenue, New York City., ...
... Feb. 29 TITAN Technology Partners, a,global provider ... the,fastest growing technology company in North Carolina in ... recognized health system,has signed a multi-year agreement to ... Financial and Human Capital Management,applications throughout the organization ...
... music industry,veteran and TV personality, is coming to ... about type 2 diabetes and its connection to,cardiovascular ... Heart,Association to speak on behalf of The Heart ... with type 2 diabetes manage the disease and,reduce ...
... Genoptix, Inc.,(Nasdaq: GXDX ), today announced the pricing ... certain existing stockholders to,the public at the price of ... from the sale. The offer is expected to close ... through an underwriting syndicate led by,Lehman Brothers, Inc. acting ...
... Feb. 29 Finesse Solutions, LLC and,Applikon ... the,TruConnect(TM) gateway, a migration device designed to ... ADI 1030 Controllers, and the Finesse,TruLogic(TM) Controller, ... control.), TruConnect(TM) gateways harmonize an installed ...
... Southwestern Medical Center have determined that the level, or saturation, ... with sickle cell anemia who are at an increased risk ... also found that a published method used to predict severe ... Stroke is a serious but increasingly preventable complication of sickle ...
Cached Medicine News:Health News:Valley Baptist Health System Leveraging TITAN Technology Partners Hosting and Managed Services 2Health News:Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease 2Health News:Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease 3Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Applikon and Finesse Solutions Introduce TruConnect(TM) 2Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2
... Every Bard® Biopsy Instrument and Needle ... one important goal: a large quality, reliable ... exceptional performance, featuring ultra-sharp tips and polished ... broad selection of biopsy systems and needle ...
... Used to obtain multiple core biopsies ... biopsy needle is designed to fit ... micro-sharpening process that produces an ultrasharp ... histological cores. Uni-Cor™ has an etched ...
... offers a customized approach to performing ... associated with current stranded products as ... seed and spacer implant techniques.SourceLink™ Connectors ... quantity and seed activity level (in ...
... is designed to bring efficiency and quality ... combines the superior technology of fluorescent flow ... Continuous sampling or batch processing are ... sample processing in high volume laboratories. ...
Medicine Products: